

ABSTRACT OF THE DISCLOSURE

The present invention relates to a method of treating a  
5 patient suffering from a neoplastic disease state  
comprising administering to said patient an effective  
antineoplastic amount of a 2'-halomethylidene derivative in  
conjunctive therapy with an effective antineoplastic amount  
of a S phase or M-phase specific agent.

10

1. *1,4-bis(2-chloroethyl)benzene* is a product  
obtained with the United States Patent Office to  
Exodus Mail in an exclusive agreement to  
Assignee Company for *2'-halomethylidene* Methylidene  
D.C. 5031, on

15

Abstract of Disclosure

Structure

Claims

20

25

30

35